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A 26-year-old woman is referred to the Internal Medicine consultation due to increases in laboratory studies associated with
PapillaryThyroid Carcinoma (PTC) that was confirmed by histopathological studies. Her clinical history revealed that, at 3 months
of age, she was successfully treated with surgery for cleft lip (CL) and at the age of 24 years was diagnosed with hypothyroidism.
Single nucleotide polymorphisms (SNPs) in FOXE1 and its promoter regions have been associated with various etiologies related
to the thyroid, including orofacial clefting, specially cleft palate (CP) and CL, hypothyroidism (HT), and thyroid cancer. The
association of CL, HT, and PTCmight be component of a new syndrome; however FOXE1 coding region, which has been involved
with these entities, has not exhibited mutations or SNPs. Further study of other genes may help in better characterization of the
possible syndrome.
1. Introduction
Transcription factors NKX2-1, FOXE1, HHEX, and PAX8
are involved in cellular differentiation during embryogenesis.
They play a critical role in themorphogenesis, differentiation,
and maintenance of the thyroid gland. The FOXE1 gene
encodes for a transcription factor protein that is expressed
from the embryonic stage in the thyroid primordium until
the development of the thyroid gland by the regulation
of thyroid promoters [1]. Single nucleotide polymorphisms
(SNPs) in this gene and its promoter regions have been
associated with various etiologies related to the thyroid,
including orofacial clefting, especially cleft palate (CP) and
cleft lip (CL), hypothyroidism (HT), and thyroid cancer (TC).
CP and CL are common birth defects, particularly in
Asian and Native American population, which have the
highest rates of prevalence, in contrast to African population,
which has the lowest. Both have a complex etiology, in
that they possess multigenetic and multifactorial causes that
have not been elucidated. However, research and mapping
of the 9q22-q33 guided the associations with several SNPs
located in the FOXE1 locus [2]. Actually, the genotypes
involving the commonest alleles of rs3758249 (GG) and
rs4460498 (CC) were the most associated with CP in Cau-
casian and Asian derived populations [3–5]. To note, both
SNPs are located in a high linkage disequilibrium (LD)
region, which also harbors the rs1867277 (−283G>A FOXE1)
SNPs that have been reported as functional in thyroid cancer
[6].
HT is the most common thyroid disorder. It is char-
acterized by low production of thyroid hormones T3 and
T4. Through Genome-Wide Association Studies (GWAS),
various polymorphisms, including SNP located in the FOXE1
gene, have been identified with problems in the formation
and differentiation of the thyroid, producing a predisposition
to the disease [5].
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Figure 1:The imaging studies showedmultinodularity (US) (a) and thyroid growth (CAT) (b). Arrows in (b) show an enlarged thyroid gland.
Figure 2: Thyroid fine needle aspiration (FNA) biopsy.
TC is the most common endocrine malignancy, with a
strong genetic component that has been shown to extend
beyond the nuclear family. Histologically, it is classified as
Papillary (PTC), Follicular (FTC), and Medullary (MTC)
Carcinomas, and undifferentiated anaplastic thyroid carcino-
mas, and studies have suggested that gender, age, tumor size,
histologic type, tumor infiltration, and vascular/lymphatic
invasion affect clinical outcome and treatment options [13].
Evidence in multiple ethnicities has associated SNP with the
same LD region as FOXE1 with PTC and MTC [1, 6]. The
case described here represents unexpected combination of
CL, HT, and PTC.
2. Case Report
A 26-year-old woman from Jalisco (Mexico) is referred
to the Internal Medicine consultation due to increases in
laboratory studies associated with PTC. Her clinical history
revealed that, at 3 months of age, she was successfully
treated with surgery for CL, at 14 years of age underwent a
cholecystectomy, and at the age of 24 years was diagnosed
with HT. In April 2016, her clinical examinations revealed
that she had anti-thyroglobulin antibodies (>4,000 𝜇g/L) and
anti-peroxidase antibodies > 42 IU/mL (normal reference
value, 34). Imaging studies demonstrated multinodularity
(Ultrasound [US]) (Figure 1(a)), discrete thyroid growth
(Figure 1(b)) and the thyroid fine needle aspiration (FNA)
biopsy corroborated PTC Bethesda Class V (Figure 2).
Based on the contribution of FOXE1 mutations and
SNPs variants (Figure 3) in the development of the CL,
HT, and PC, we sequenced the exon 1 of this gene (coding
region and 3󸀠UTR) in order to identify mutations or SNPs
potentially associated with the patient’s diseases. At the
Research Laboratory of Cipre´s Grupo Me´dico S.C. (CGM),
GenomicDNAwas isolated fromperipheral white blood cells
using the DNA purification kit (Quick-DNA Miniprep Plus
Kit, Zymo Research Corp) according to the manufacturer’s
instructions. At the INMEGEN Exon 1 of FOXE1 gene was
analysed using the primers described in Table 1. PCR was
performed in a final volume of 50𝜇l, using 50 ng of genomic
DNA, 2.5 pmoles of each primer, 2mM of each dNTP, 1 U
of AmpliTaq Gold DNA Polymerase, 4mM MgCl
2
, and 10x
PCR Gold buffer (Applied Biosystems provided polymerase,
MgCl
2
, and buffer). Cycling conditions for PCR consisted
of a first denaturation step of 95∘C for 10min, followed
by 35 cycles of denaturation at 95∘C for 20 s, annealing at
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Table 1: Sequence of the primers used.
ID Sequence Length Tm Amplicon
1F GTCACTCCCGAGCCTCTGT 19 60.41 395 pb
1R GTAGCTGTAGGGCGGCTTC 19 59.99
2F AGCCGCCCTACAGCTACAT 19 59.87 488 pb
2R CGCGGGGTAGTAGACTGG 18 59.26
3F GCCGTCTATGCAGGCTACG 19 61.8 639 pb
3R GGGTCCCAGTTGAGTCCTCT 20 60.5
F: forward; R: reverse.
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Figure 3: Diagram of the FOXE1 region marking some single nucleotide polymorphisms (SNPs) reported.The 5󸀠 and 3󸀠 untranslated regions
(UTR) are marked in a blue box, the FOXE1 gene exon is marked in an orange box, the forkhead region is marked in a red box, and the SNPs
present in our patient are marked in italic.
60∘C for 20 s, and extension at 72∘C for 30 s, followed by
a final extension at 72∘C for 7min. The runs were carried
out on a GeneAmp PCR system 9700 (Applied Biosys-
tems). PCR products were sequenced directly with a DNA
Sequencing Kit with Big Dye Terminator on an automated
ABI 3730XL sequencer (Applied Biosystems, Foster City,
CA, USA) and data analyses were performed by Lasergene
software (DNASTAR Inc.). Neither mutations nor SNPs were
found in FOXE1 coding region. Two SNPs (rs1867279 and
rs1867280) that have already been associated with CP were
found in a homozygote wild type genotype. Additionally,
we found the rs71369530 (Ala-14) in homozygote fash-
ion. Functional prediction analysis using the SNPinfo Web
Server (https://snpinfo.niehs.nih.gov/snpinfo/snpfunc.html)
showed that only the ancestral alleles of rs1867279 and
rs1867280 might recruit the E2F and NFKB transcription
factors, respectively.
3. Discussion
3.1. Generalities. Several studies in genetics have shown that
HT, TC, and isolated CL and CP are related to the FOXE1
locus. FOXE1 (Forkhead box E1; UniGene accession number
Hs.159234) is an intron-less single exon gene that encodes
transcription factor FOXE1 (or TTF-2). FOXE1 is an 373
amino acid protein (38 kDa) that contains a forkhead winged
helix DNA binding domain and a polyalanine (polyAla) tract
of variable length (11–19Ala, but 14-Ala ismost abundant) and
negatively regulates thyroglobulin (TG) and Thyroid Peroxi-
dase (TPO) expression, which regulates, in conjunction with
NKX2-1 (Homeobox protein or TTF-1), PAX8, and HHEX,
thyroid differentiation and function [9, 17].
RNA in situ hybridization studies in zebrafish in the
fish ortholog of FOXE1, foxe1, indicated that during the
postfertilization development, the gene is early expressed in
the nervous system, afterward in the oral epithelium and
thyroid gland, later in the developing heart, and, in the
final stages, in the pharyngeal arch epithelium [5]. Moreover,
phenome-wide association studies of genotypes of electronic
medical records in DNA biobanks have associated the FOXE1
locus with thyroiditis, nodular and multinodular goiters, and
thyrotoxicosis, among others [18], indicating that mutations
in this gene and its promoters exert an important effect on
normal thyroid function.
3.2. Orofacial Clefts. Orofacial clefts (OC) comprise clefts,
disruption, or gaps in structures such as lips, palate, eyes,
and nose and arise from failure of normal craniofacial
development, in which cells grow, migrate, and differentiate
in a coordinated fashion to fuse together the lateral, medial,
and maxillary processes. Moreover, given the different devel-
opmental origins of lip and palate, these are classified in CL
with or without CP [19].
Isolated CL and CP are common genetic defects with
a strong genetic component that has not been completely
elucidated, and approximately 70–80% of CL/CP that are
nonsyndromic (absence of additional structural or cognitive
abnormalities) represent complex human disorders with
the interaction of genetic risk factors and environmental
exposures that increase susceptibility [19]. Evidence suggests
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that rare DNA variations in several genes and SNPs (many of
these are present in noncoding DNA) are linked to CL and
CP etiology [3, 8].
3.3. Relation of FOXE1 with Orofacial Clefts. Genome-wide
association studies (GWAS) have related FOXE1 with CL
and CP in different population, within the region 9q22-
33 [3, 5, 8]; however the SNP and haplotype frequencies
found within each population indicate multiple risk alleles
for such a complex disease, due in part to maternal or
paternal overtransmission [3]. Moreover, as its role with the
expression of TG and TPO suggests, mutations at the FOXE1
locus in 9q22 have been associated with thyroid disorders
such as congenital HT due to thyroid dysgenesis, primary
HT, goiters, nonmedullary thyroid cancer, PTC, and TC
[5, 8].
FOXE1 is responsible for palatogenesis, and it appears
that casual mutations in noncoding regions that regulate
FOXE1 expression are related to CL and CP [3], such as SNPs
rs7850258, rs12342417, and rs10984103 within the FOXE1
locus that have been associated with high risk for orofacial
clefting [8].
Few studies have been carried out onMexican population
or in persons with American-Indian ethnicity; however,
research has shown that SNP rs4460498 and rs375829,
located in the FOXE1 locus, are associated with nonsyn-
dromic CP and CL for European and Mayan-Mesoamerican
descendants [7]. This study obtained important significance
in high risk of CL/CP for rs4460498 𝑝Europe = 6.50 × 10
−6
and 𝑝Mayan = 0.051, and for rs375829 𝑝Europe = 2.41 × 10
−5 and
𝑝Mayan = 0.0299.
3.4. Relation of FOXE1 with Hypothyroidism. HT is the
most common thyroid disorder characterized by deficien-
cies of thyroid hormones T3 and T4 (triiodothyronine and
thyroxine, resp.), which are regulators of metabolism and
development. A common marker of HT is the high levels
of Thyroid-Stimulating Hormone (TSH), which indicate
impaired thyroid function; however, in other cases, reduced
levels of TSH cause low levels of T3 and T4. Iodine deficiency
is the most common cause of HT, but congenital HT and
autoimmune HT are other varieties with different genetic
causes [20] that cause central HT, primary HT, alterations in
thyroid transcription factors (with which the FOXE1 gene is
associated), dyshormonogenesis, and other genes such as the
TG and TSH genes [19].
A mutation in the coding sequence of FOXE1 that shifts
Arginine-102 to a Cysteine (R102C), a highly conserved
residue within the forkhead domain of the protein, impairs
FOXE1 from binding DNA; thus, it is inactive toward tran-
scription. This inactivity leads to thyroid dysgenesis in the
patient, which causes congenital HT, CP, spikey hair, and
bilateral choanal atresia. Interestingly, because athyreosis is
not present, human thyroid formation and development do
not depend entirely on FOXE1 activity [21].
SNPs that are present in other autoimmune diseases,
such as rs6679677 near PTPN22, rs3184504 in SH2B3, and
rs2517532 in HLA class I region, are linked to HT, while
rs4915077 near VAV3 [20] and other SNPs such as rs7850258,
rs965513, rs925489, and rs10759944, all located near FOXE1
in chromosome 9, exhibit genome-wide significance with
primary HT [18]. Other SNPs in chromosome 9 that appear
to be associated with primary HT are rs4979402, rs4979397,
rs1408528, and rs1535971, located in DFNB31 that is 16.6Mb
from FOXE1 and not in LD with other SNP of FOXE1;
however, these later regions do not correlate when TSH is not
expressed [18].
3.5. Relation of FOXE1 with Thyroid Cancer. TC is a complex
polygenic disorder and the networking of the molecular
mechanisms involved in its development, the genes involved
in the process, and the risk environmental factors remain to
be understood. It has been proposed that TC is the result
of multiple low-to moderate penetrance genes interacting
with each other, acting together with other transcriptional
regulators that produce loss- or gain-of-function and that,
together with environmental and other genetic risk factors,
can lead to the development of cancer [6, 14, 21]. However,
this explains only a small portion of the incidence, as there
are other genetic factors involved. TC types, such as FTC,
Differentiated Thyroid Cancer (DTC, which includes PTC
and MTC), and undifferentiated anaplastic thyroid carcino-
mas, have different biomarkers and cellular conformations
and thus different molecular pathways involved in their
development.
rs7850258, located in the FOXE1 promoter region near
craniofacial enhancer hsCNE-67, has direct involvement in
the development of thyroid and heart, and is also associated
with HT and TC, as it was found to alter the enhancer
function in both oral epithelial and thyroid cell lines. In this
SNP, allele G is associated with HT and CL, whereas allele A
is associated with TC [5].
Studies in several countries [6, 9–11, 14–16] have revealed
that FOXE1 locus polymorphisms in chromosome 9q22.33,
such as rs965513 and polymorphisms (rs7849497, rs1867277,
rs1867278, rs1867279, and rs1867280) in the promoter regions
for this factor are associated with an increased risk of non-
medullary thyroid cancer, differentiated thyroid cancer, and
the Bamforth–Lazarus syndrome, in which the mutation of a
serine-57 to asparagine (S57N) in the forkhead-DNAbinding
domain of FOXE1 leads to CP, choanal atresia, bifid epiglottis,
thyroid agenesis or dysgenesis, hypothyroidism, and spikey
hair [22]. Although there is no clear evidence of the role of the
rs1867279 and rs1867280 in CL, HT, and PTC pathogenesis,
functional prediction analysis showed that both SNPs could
modify the transcription factor binding site and thus modu-
late the expression of relevant genes in the thyroid morpho-
genesis. Otherwise, the rs1867279 and rs1867280 might be in
LD with the true casual variant, such as rs1867277, because
a high LD has been described in the FOXE1 region. On this
regard, it has been reported that the rs1867277A allele recruits
the USF1/USF2 transcription factors and has been shown
to be involved in an allele-specific transcriptional regulation
of FOXE1 in thyroid cancer [6]. Actually, the rs1867277
have been found related to TC in several populations
[21, 23, 24].
Case Reports in Genetics 5
The information about the association of the FOXE1 SNP
rs1867277 with TC appears to vary with ethnicity and cancer
type [16, 23]. For example Bychkov et al. [12] found overex-
pression of rs1867277 and rs965513 by immunohistochemical
staining in PTC in Japanese persons. On the contrary, neither
Maillard et al. [14] in French Polynesians nor Bonora et al.
[25] in European descendants found an association of this
SNP with nonmedullary thyroid cancer.
SNP rs1867277, within the −283G>A promoter region,
was assessed functionally by Landa et al. [6] and their results
suggest that this SNP increases the transcriptional activity of
the FOXE1 gene promoter by recruitment of leucine zipper
USF 1 and 2. Thus, it is likely that recruiting USF1 and USF2
proteins produces a deregulation of FOXE1 that leads to
malignant behavior of thyroid cells [9].
It is been demonstrated that, through a number of
signalling pathways, FOXE1, along with the remainder of the
family of FOX transcription factors, can induce WNT5A, a
gene (located in 3p14.3) expressed in a variety of human
tumors [26]. Thus, by deregulation of FOXE1, it is likely
that this protein can become a tumor suppressor or an
oncogene through the Wnt pathway, either dependently or
independently of 𝛽-catenin [17]. Also, there is evidence
that the RET/PTC3 protooncogene that causes TC decreases
FOXE1 expression. Similarly, in squamous cell carcinoma, the
9q22 region of the chromosome (where FOXE1 is localized)
is lost and, in other cancers, hypermethylation of promoter is
also observed [5].
Levels of FOXE1 and PAX8 messenger RNA (mRNA)
in thyroid nodules have been found to be decreased in
malignant thyroid lesions and higher in benign lesions,
and even the gene expression patterns of FOXE1 and PAX8
can help in differentiating FTC from MTC and the Fol-
licular Variant of Papillary Thyroid Carcinoma (FVPTC)
[27].
Because we did not sequence the entire gene, our anal-
ysis did not exclude the hypothesis that FOXE1 mutations
contribute to the development of these diseases. Numerous
evidences have been published suggesting that this gene
is involved in these three diseases. In the same haplotype
analysis of the members of a Portuguese family with non-
medullary thyroid carcinoma, the selected individuals with
the disease not only shared the FOXE1 p.A248G variant,
but also the same haplotype between markers rs965512 and
D99S180 (located in chromosome 9), including rs1867279
and rs1867280 (SNPs present in our patient). However, these
persons did not exhibit an association with any of the other
polymorphic loci with the cancer because, as according to
the authors and as reported in a previous paper, 15% of
Portuguese control population have these SNP [17]. However,
we propose that ethnicity and environmental factors are very
important in triggering a disruptive response in rs1867279
and rs1867280, as in the case of our patient, in whom these
SNPs are acting together, along with other risk factors (ethnic
and environmental), to produce CL, HT, and TC.
Given the puzzling findings reported with rs1867277 [12,
16, 22] in FOXE1 or rs944289 in NKX2 [15], it is obvious that
ethnicity and environmental factors play a key role for the
development of TC and other malignancies. Additionally, the
involvement of FOXE1 in thyroid formation and function, as
well as the formation of craniofacial structures, relates muta-
tions in the noncoding region of FOXE1 to the phenotype of
our patient.
Evidence such as the Bamforth–Lazarus syndrome [22],
or mutations in FOXE1 that explain an association of
hypothyroidism and cleft palate [28], in addition to obser-
vational and comparative data of human and animal models
null for Foxe1 [5, 29] that are consistentwithCP, CL, and other
thyroid abnormalities, suggests that mutations or SNP in
FOXE1 can be a common cause for a possible new syndrome
characterized by CL, HT, and PTC. In this line, Tables 2 and 3
illustrate some of the most studied SNPs and genes probably
associated with these diseases.
Seeking an explanation for the possible identification of
the syndrome that has been discussed, the FOXE1 mutation
has been tested, being negative as far as could be analysed. A
possible candidate gene in this situation is E-cadherin CDH1
on 16q22.1, which is also expressed in critical stages of lip
and palate development in embryos [30, 31]. Hence, there are
manymore genetic alterations that could explain this possible
association.
4. Conclusions
The association of CL, HT, and PTC might be component of
a new syndrome; however FOXE1 coding region, which has
been involvedwith these entities, has not exhibitedmutations
or SNPs. Based on this case study and a review of the literature
on the role that the FOXE1 gene plays in these patholo-
gies, a more extensive sequence analysis (including other
genes) is needed to rule out its role in the above-mentioned
diseases.
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Table 3: Genes related to orofacial clefts: cleft lip (CL) and cleft
palate (CP), papillary thyroid cancer, or hypothyroidism.
Pathology Genes
Orofacial clefts CL/P
BMP4
CRISPLD2
FGF8
FGFR1
FGFR2
FOXE1
GLI2
GSTM1
GSTT1
JAG2
LHX8
MSX1
MSX1
MSX2
NAT1
NAT2
PTCH
PVRL1
RYK
SATB2
SKI
SPRY2
TBX10
TGFB3
Papillary thyroid cancer
ATM
NKX2
RET (RET/PTC
rearrangement)
Hypothyroidism
DFNB31
PTPN22
SH2B3
VAV3
questions related to the accuracy or integrity of any part of
the work are appropriately investigated and resolved.
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